Publication:
Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions.

dc.contributor.authorNicoletti, Paola
dc.contributor.authorBarrett, Sarah
dc.contributor.authorMcEvoy, Laurence
dc.contributor.authorDaly, Ann K
dc.contributor.authorAithal, Guruprasad
dc.contributor.authorLucena, M Isabel
dc.contributor.authorAndrade, Raul J
dc.contributor.authorWadelius, Mia
dc.contributor.authorHallberg, Pär
dc.contributor.authorStephens, Camilla
dc.contributor.authorBjornsson, Einar S
dc.contributor.authorFriedmann, Peter
dc.contributor.authorKainu, Kati
dc.contributor.authorLaitinen, Tarja
dc.contributor.authorMarson, Anthony
dc.contributor.authorMolokhia, Mariam
dc.contributor.authorPhillips, Elizabeth
dc.contributor.authorPichler, Werner
dc.contributor.authorRomano, Antonino
dc.contributor.authorShear, Neil
dc.contributor.authorSills, Graeme
dc.contributor.authorTanno, Luciana K
dc.contributor.authorSwale, Ashley
dc.contributor.authorFloratos, Aris
dc.contributor.authorShen, Yufeng
dc.contributor.authorNelson, Matthew R
dc.contributor.authorWatkins, Paul B
dc.contributor.authorDaly, Mark J
dc.contributor.authorMorris, Andrew P
dc.contributor.authorAlfirevic, Ana
dc.contributor.authorPirmohamed, Munir
dc.date.accessioned2024-02-10T20:01:51Z
dc.date.available2024-02-10T20:01:51Z
dc.date.issued2019-07-03
dc.description.abstractCarbamazepine (CBZ) causes life-threating T-cell-mediated hypersensitivity reactions, including serious cutaneous adverse reactions (SCARs) and drug-induced liver injury (CBZ-DILI). In order to evaluate shared or phenotype-specific genetic predisposing factors for CBZ hypersensitivity reactions, we performed a meta-analysis of two genomewide association studies (GWAS) on a total of 43 well-phenotyped Northern and Southern European CBZ-SCAR cases and 10,701 population controls and a GWAS on 12 CBZ-DILI cases and 8,438 ethnically matched population controls. HLA-A*31:01 was identified as the strongest genetic predisposing factor for both CBZ-SCAR (odds ratio (OR) = 8.0; 95% CI 4.10-15.80; P = 1.2 × 10-9 ) and CBZ-DILI (OR = 7.3; 95% CI 2.47-23.67; P = 0.0004) in European populations. The association with HLA-A*31:01 in patients with SCAR was mainly driven by hypersensitivity syndrome (OR = 12.9; P = 2.1 × 10-9 ) rather than by Stevens-Johnson syndrome/toxic epidermal necrolysis cases, which showed an association with HLA-B*57:01. We also identified a novel risk locus mapping to ALK only for CBZ-SCAR cases, which needs replication in additional cohorts and functional evaluation.
dc.format.number5es_ES
dc.format.page1028-1036es_ES
dc.format.volume106es_ES
dc.identifier.doi10.1002/cpt.1493
dc.identifier.e-issn1532-6535es_ES
dc.identifier.journalClinical pharmacology and therapeuticses_ES
dc.identifier.otherhttp://hdl.handle.net/10668/13926
dc.identifier.pubmedID31066027es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/17887
dc.language.isoeng
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshAdult
dc.subject.meshAnaplastic Lymphoma Kinase
dc.subject.meshCarbamazepine
dc.titleShared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions.
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication

Files